Previous 10 | Next 10 |
CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced ...
Image source: The Motley Fool. Mersana Therapeutics, Inc. (NASDAQ: MRSN) Q1 2020 Earnings Call May 08, 2020 , 8:00 a.m. ET Operator Continue reading
The need for capital continues apace for healthcare companies as they deal with COVID-19 disruptions. More news on: Check-Cap Ltd., Cellectar Biosciences, Inc., BioTelemetry, Inc., Healthcare stocks news, , Read more ...
The following healthcare companies have recently filed for mixed shelf offerings: More news on: Clearside Biomedical, Inc., Mersana Therapeutics, Inc., Arcturus Therapeutics Holdings Inc., Healthcare stocks news, , Read more ...
Mersana Therapeutics, Inc. (MRSN) Q1 2020 Earnings Conference Call May 8, 2020 08:00 AM ET Company Participants Sarah Carmody – Executive Director-Investor Relations and Corporate Communications Anna Protopapas – President and Chief Executive Officer Dirk Huebner ...
Recently presented promising XMT-1536 Phase 1 dose escalation data and established maximum tolerated dose, subsequently raising $65M of gross proceeds from the Company’s ATM facility Company to present interim data from the ongoing XMT-1536 Phase 1 dose expansion on a conferenc...
CAMBRIDGE, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announce...
Mersana Therapeutics (NASDAQ: MRSN ) initiated with Buy rating and $14 (50% upside) price target at BTIG Research. Shares up 2% premarket. More news on: Mersana Therapeutics, Inc., Viela Bio, Inc., Y-mAbs Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Rea...
The S&P 500 gained slightly last week as optimism about a V-shaped economic recovery increased. As written in my recent article , I'm skeptical about the recent market surge as I believe the economy could keep being weak for a longer period of time. However, I believe it could be inte...
Amid widespread uncertainty in healthcare around COVID-19 impact, Baird is focusing on clinical catalysts that continue to power biotech picks - and in particular it's declaring fresh picks on two stocks with data forthcoming. More news on: Constellation Pharmaceuticals, Inc., Blueprint Me...
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...